News Related to United Biotechnology

Related coverage linked through entity extraction aliases.

Novo Nordisk Reports 20% Weight Loss With Experimental Triple-Action Obesity Drug

Feb 24, 2026

Novo Nordisk's experimental triple-action obesity drug UBT251 achieved up to 19.7% weight loss in a Phase 2 trial in China, as the company works to regain ground against rival Eli Lilly in the obesity drug market.

Novo Nordisk and United Laboratories Report Weight Loss Results for Obesity Drug UBT251

Feb 24, 2026

Novo Nordisk and China's United Biotechnology reported that experimental obesity drug UBT251 led to mean weight loss of up to 19.7% in a midstage clinical trial in China, expanding Novo's obesity pipeline.